In Reply The letter from Pfeffer et al outlines the authors’ rationale for their belief that the AA genotype for the rs1967309 single-nucleotide polymorphism (SNP) in the ADCY9 gene is likely associated with a cardiovascular benefit in patients treated with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib. We believe that our analysis1 of the evacetrapib outcome trial provides a more precise and reliable estimate of any association between this SNP and cardiovascular outcomes in patients treated with CETP inhibitors. Our analysis had more cardiovascular events in patients treated with a CETP inhibitor with the AA genotype (n = 125) compared with the dalcetrapib analysis (n = 38).2 Estimates of relative risk based on only 38 events are statistically unstable and inherently low in reliability.
Nissen SE, Pillai SG. Randomized Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype—Reply. JAMA Cardiol. 2018;3(9):897–898. doi:https://doi.org/10.1001/jamacardio.2018.2382
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: